Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes
Primary result · Increase in urinary glucose excretion with SGLT2 inhibitionResult — go to the resultDifference 1.0 g 95% CI −3.5 to 5.6Authors' conclusion
The robust effect of SGLT2 inhibition on urinary glucose excretion in participants with HNF1A-MODY points to SGLT2 inhibition as a relevant glucose-lowering treatment strategy in individuals with HNF1A-MODY.
Study context
- Population
- Individuals with HNF1A-MODY or T2D undergoing two three-step hyperglycemic clamps (10, 14 and 18 mmol/L glucose) with empagliflozin 25 mg or placebo 2 h before
- Participants
- 11 vs 10
- Comparison
- Acute SGLT2 inhibition (empagliflozin 25 mg) vs placebo during hyperglycemic clamp, in HNF1A-MODY and T2D
- HNF1A-MODYn = 11
- Type 2 diabetesn = 10reference
- Primary endpoint
- Effect of acute SGLT2 inhibition on urinary glucose excretion
- Follow-up
- 3-h hyperglycemic clamp
Methodological detailsdouble-blind, three-step hyperglycemic clamps
- Double-blind
- Three-step hyperglycemic clamps
Primary result
As reported in the abstract
Increase in urinary glucose excretion with SGLT2 inhibition
Difference
1.0 g
95% CI −3.5 to 5.6
P = 0.6
By group
HNF1A-MODYvs Type 2 diabetes
difference 1.0 g (95% CI −3.5 to 5.6); P = 0.6
Original publication
Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes. Diabetes Care. Published 3 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →